Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease

BACKGROUND: Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can pre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Inflamm Bowel Dis
Autors principals: Bauman, Laura E, Xiong, Ye, Mizuno, Tomoyuki, Minar, Philip, Fukuda, Tsuyoshi, Dong, Min, Rosen, Michael J, Vinks, Alexander A
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7171445/
https://ncbi.nlm.nih.gov/pubmed/31287855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izz143
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars